Introduction: Vertebral compression fracture incidence is rising with the growth of the geriatric population and is one of the leading disabilities in healthcare. However, the literature is conflicted on the benefits of vertebral augmentation versus nonoperative care for these fractures. The purpose of the current study was to perform a review of all meta-analyses in the literature comparing vertebral augmentation to nonoperative care and descriptively report the results.
Introduction
Vertebral compression fractures (VCFs) are the most common type of fractures seen with osteoporosis. While only 30%-40% of VCFs are symptomatic, the resulting back pain can severely limit a patient's ability to perform activities of daily living 1) . Percutaneous vertebral augmentation (PVA) is an intervention used to treat osteoporotic or pathologic VCFs. Two types of PVA are used: vertebroplasty (VP) and kyphoplasty (KP). VP involves the injection of cement into the affected vertebral body, while KP involves the inflation of a surgical balloon to create a cavity and, in some cases, correct the deformity prior to cement injection. Risks of PVA include direct nerve injury, cement extravasation, bleeding, and embolic events 2) . The goal of PVA is to stabilize the fracture to manage the debilitating symptoms associated with VCFs, and, with KP, improve the deformity, if possible. Retrospective studies have shown that both KP and VP provide effective pain reduction in patients suffering from VCFs 3, 4) . In 2009, two randomized controlled trials (RCTs) published by Buchbinder et al. and Kallmes et al. in the New England Journal of Medicine reportedly showed that VP had no benefit over a sham procedure in patients suffering from back pain, presumably due to VCFs 5, 6) . Since then, the role of VP and PVA in treating osteoporotic VCFs has been controversial. A systematic review published in 2012 by Maturitas studying RCTs concluded that PVA provided significant pain relief compared with placebo or nonsurgical manage- . However, it should be noted that the trials that reported benefit in PVA did not use sham controls, while Buchbinder and Kallmes 5, 6) did use sham controls. As of August 2017, in the past 2 years no trials that assess PVA outcomes were reported. The objective of this review is to present and discuss the findings of meta-analyses that have examined the question of PVA efficacy in treating of VCFs, due to the lack of consensus on its efficacy.
Materials and Methods
Meta-analyses available in English full text on PubMed that examined human trials comparing the efficacy of PVA (VP, KP, or both) with placebos or nonsurgical management were included for review. The primary outcome examined was pain scores. Secondary outcomes included quality of life (QoL) and functional scores.
The following search terms were used in PubMed to obtain our studies:
( 
Results

Description of studies
The search yielded 57 studies that reviewers checked for inclusion by reading through the studies' abstracts. 45 were excluded because they either did not compare PVA to nonsurgical treatments or placebo or because they did not examine efficacy. The remaining 12 studies underwent full text review. One study was excluded for including non-PVA surgical procedures in its meta-analysis, while another was excluded because it was not a meta-analysis. The 10 remaining meta-analyses were reviewed and discussed. All 10 studies included were meta-analyses of prospective trials examining the efficacy of VP, KP, or both compared with control cohorts. A summary of the inclusion and exclusion process is shown in Fig. 1 . Of the 10 meta-analyses, three compared both VP and KP against control cohort [8] [9] [10] and seven compared VP to control cohorts [11] [12] [13] [14] [15] [16] [17] . Characteristics and findings of the 10 studies are summarized in Table 1 . When combined, the 10 meta-analyses examined a total of 22 trials. The distribution of these trials among the 10 meta-analyses is shown in Table 2 .
Of the 22 trials, three used sham surgical procedures as their control groups. These studies are marked in Table 2 . The remaining 18 studies used nonsurgical management as their control groups.
Pain outcomes
All three meta-analyses that compared PVA with control concluded that PVA provided a statistically significant improvement in pain outcomes compared with controls. Of the seven meta-analyses that compared only VP with control, two concluded that no statistical difference in pain outcomes could be seen between VP and control group 12, 17) . The remaining five all concluded that VP reduced pain significantly more than in control groups 11, [13] [14] [15] [16] .
Functional outcomes
Of the three PVA meta-analyses, one examined functional outcomes and concluded that PVA afforded significant improvement in functional outcomes compared with controls 8) .
The two VP meta-analyses that reported on functional outcomes both concluded that no difference in functional outcomes existed between VP and control groups 12, 17) .
QoL outcomes
QoL measurements include pain-related disabilities, European Quality of Life-5 Dimensions, Quality of life Questionnaire of the European Foundation for Osteoporosis, and Roland-Morris Disability Questionnaire 8, 9, 15) . Only two out of the three PVA meta-analyses studied QoL; both found that PVA provided statistically significant better outcomes. There were three VP meta-analyses that studied QoL, two concluded PVA led to significantly better QoL, while one found no statistically significant difference in QoL outcomes.
Discussion
PVA, including both KP and VP, is frequently used to treat acute VCFs; however, there has been recent controversy over its efficacy. showed no benefit to patients suffering from back pain compared with outcomes from a sham procedure control group 5, 6) . These studies likely went on to influence practices, with the American Academy of Orthopaedic Surgeons noting that evidence supporting kyphoplasty in treating VCFs was limited but issued a strong recommendation against vertebroplasty 37) . The purpose of our study is to re-examine the conclusions set forth by Buchbinder and Kallmes in the context of other meta-analyses comparing PVA with nonoperative care. A total of 10 meta-analysis were examined, three comparing PVA with nonoperative care, seven comparing VP-only with nonoperative care. Of the 10 meta-analyses, 8 studies concluded that either PVA or VP conferred better pain outcomes than nonoperative care. Of the two that did not, one was Buchbinder et al.'s 2015 assessment that concluded that RCTs that did not use a sham procedure control were subject to bias. Therefore, less weight was placed on RCTs that did not use sham procedures. The other, by Staples et al., only included the two aforementioned studies by Buchbinder et al. and Kallmes et al 17) . Both Buchbinder et al. and Kallmes et al.'s rationales were that a sham procedure was the only proper control for a RCT studying the efficacy of VP.
There are concerns with this approach. First, using only two studies greatly diminishes the power of Staples et al.'s meta-analysis. Second, a study published in 2015 by Guo et al. in the Public Library of Science noted that, while sham procedures such as the one documented by Buchbinder et al. 5) and Kallmes et al. 6) are intended to be used as a control, they are still invasive procedures that can contribute a placebo effect in patients suffering from VCF-induced pain 38) . When vertebroplasty and sham procedure groups were considered together with other surgical procedures, pain outcomes were significantly better than those seen in nonsurgical management. Third, the inclusion criteria used by Buchbinder et al. and Kallmes et al. in their respective RCTs are concerning. Both studies included patients with back pain but failed to describe whether the back pain was confirmed to be caused by VCFs through clinical examination, the acuity of the fractures through history or advanced imaging (MRI and/or bone scan). Neither MRIs nor bone scans were performed at any time, either during preprocedure in assignment or postprocedure, to determine whether the polymethylmethacrylate had extravasated or new fractures had developed. The entry criteria were back pain and plain radiographs demonstrating a VCF. However, the latter could have occurred at any time and/or completely healed and just incidental. The back pain could have been from many other causes. Also, without examining the patient they would not know if the pain was even at that location. Thus, there is a risk that patients who did not suffer from pain due to VCFs or patients with chronic/healed fractures were included, thus confounding pain outcomes. Moreover, the studies exhibited crossover rates toward VP as high as 47%. Moreover, 40%-60% of patients who were truly eligible for these studies did not participate, thus bringing the generalizability of their findings into serious question. . While this review focused on meta-analyses of prospective studies on VA, retrospective studies supporting VA use exist as well. One such study examined patients diagnosed with osteoporotic VCFs between 1993 and 2006 and found that VA afforded a survival advantage over VCF patients treated with conservative management 40) . Another singlecenter retrospective study examining healthcare costs found that while VA hospital stays cost more than medical management, VCF patients managed conservatively were subject to higher readmission rates than patients treated with VA 41) . These studies, while retrospective, further support VA as an efficacious and cost-effective means of treating VCFs.
Limitations
This review is limited by the weaknesses inherent in the included meta-analyses. Most of the meta-analyses studies noted significant heterogeneity among the controlled trials that they examined. Moreover, while all meta-analyses examined pain, functional outcomes and QoL scores were not uniformly assessed in all studies. QoL, specifically, is a useful tool to assess how patients themselves perceive their level of functionality and it is important to begin to uniformly assess this. QoL assessment tools, such as the Assessment of Quality of Life scales may offer additional insight into patients' daily lives and provide a patient-centered measure of VA's efficacy when employed in future trials 42) . Different time point studies (length of follow-up) by each meta-analysis and the bias inherent in choosing which trials to include or exclude also contributes to this heterogeneity. In any case, more controlled trials are needed to conclude whether PVA can improve pain, function and QoL in pa-tients suffering from VCFs.
Conclusion
Despite limitations, the current literature suggests vertebral augmentation is more effective at reducing pain compared with nonoperative care. Both prospective and retrospective studies support the use of PVA over nonsurgical management. Moreover, by failing to discern the source of their subjects' back pain and inconsistent sampling and statistical analysis, Buchbinder et al. and Kallmes et al. cannot objectively conclude that VP offers no advantage over a sham procedure. Furthermore, their failure to provide adequate preoperative and postoperative monitoring for their patients does not meet standards of evidence-based medicine. While more studies are needed to conclusively assess vertebral augmentation's efficacy in improving functional outcome and QoL metrics, the meta-analyses surveyed here suggest that at least some benefit in these two outcomes. The papers surveyed in this study represent the current best evidence that should be used to provide individual care patients suffering from VCFs. Thus, our review demonstrates that VP and KP are procedures with proven efficacy in affecting clinically relevant patient outcomes and are therefore not only acceptable but effective strategies in managing acute VCFs. Author Contributions: WL and CC wrote and prepared the manuscript, and all other participated in the study design. All authors have read, reviewed, and approved the article.
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